Morgan, AR;
Touchard, S;
Leckey, C;
O'Hagan, C;
Nevado-Holgado, AJ;
Barkhof, F;
Bertram, L;
... Sheridan, H; + view all
(2019)
Inflammatory biomarkers in Alzheimer's disease plasma.
Alzheimer's and Dementia
10.1016/j.jalz.2019.03.007.
(In press).
Preview |
Text
Morgan-S1552526019300780-main.pdf - Published Version Download (941kB) | Preview |
Abstract
Introduction: Plasma biomarkers for Alzheimer's disease (AD)diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262)subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1)that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1)that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH)plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
Archive Staff Only
 |
View Item |
